PREVENTING PREMATURE LUTEINISING HORMONE (LH) SURGE 1




Adverse Event reporting information can be found in footer
Request a Meeting
Here you can find material to be used for teaching patients how to use Fyremadel®
A step-by-step guide which you may find helpful when demonstrating how to use Fyremadel® with your patients
SEE THE GUIDEHow to administer Fyremadel® (ganirelix acetate)
WATCH THE VIDEOAnswers to common patient queries about Fyremadel®
READ MOREJob Code: UK-RMMH-2400044 - Date of preparation: October 2024